Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
AbCellera Biologics Inc. - Common Shares
(NQ:
ABCL
)
12.40
+0.16 (+1.31%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 27, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about AbCellera Biologics Inc. - Common Shares
< Previous
1
2
3
4
5
6
7
Next >
AbCellera (ABCL) Q2 2026 Earnings Call Transcript
↗
August 12, 2026
Lead program ABCL635 Phase 2 enrollment complete with data expected in August.
Via
The Motley Fool
Topics
Earnings
Intellectual Property
Here are the top movers in Monday's session.
↗
August 10, 2026
Via
Chartmill
There are notable gap-ups and gap-downs in today's session.
↗
August 10, 2026
Via
Chartmill
AbCellera’s ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial
↗
August 10, 2026
AbCellera Biologics (NASDAQ:ABCL) reported top-line four-week results from a Phase II trial of ABCL-635, an investigational non-hormonal treatment for moderate to severe vasomotor symptoms, or hot...
Via
MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Misses Q2 Estimates, Falls Short on Revenue and EPS
↗
August 05, 2026
Via
Chartmill
AbCellera Biologics Inc (NASDAQ:ABCL) Reports Narrower-Than-Expected Loss on Patent Settlement Windfall
↗
February 24, 2026
Via
Chartmill
Topics
Intellectual Property
12 Health Care Stocks Moving In Friday's After-Market Session
↗
August 07, 2026
Gainers AbCellera Biologics (NASDAQ:ABCL) shares increased by 8.2% to $7.5 during Friday's after-market session. The company's market cap stands at $1.9 billion. As per the news, the Q2 earnings report...
Via
Benzinga
Get insights into the top gainers and losers of Friday's after-hours session.
↗
August 07, 2026
Via
Chartmill
AbCellera Biologics Q2 Earnings Call Highlights
↗
August 05, 2026
AbCellera Biologics (NASDAQ:ABCL) said it expects to report top-line data “very soon” from its Phase I study of ABCL635, an antibody being evaluated for moderate-to-severe vasomotor symptoms, or hot...
Via
MarketBeat
Topics
Earnings
AbCellera Biologics Bets on Hot Flash Antibody as Pipeline Pivot Gains Steam
↗
June 04, 2026
AbCellera Biologics (NASDAQ:ABCL) is emphasizing its transition from a partner-based antibody discovery business to a proprietary drug development company, Chief Financial Officer Andrew Booth said...
Via
MarketBeat
Earnings Scheduled For November 6, 2025
↗
November 06, 2025
Via
Benzinga
Earnings Scheduled For August 7, 2025
↗
August 07, 2025
Via
Benzinga
AbCellera Biologics Q1 Earnings Call Highlights
↗
May 11, 2026
AbCellera Biologics (NASDAQ:ABCL) said its first quarter of 2026 was marked by progress in its internal drug pipeline, including interim Phase 1 data for its lead program, ABCL635, and continued...
Via
MarketBeat
Topics
Earnings
AbCellera (ABCL) Q1 2026 Earnings Transcript
↗
May 11, 2026
AbCellera (ABCL) Q1 2026 Earnings Transcript
Via
The Motley Fool
Topics
Intellectual Property
Stay updated with the stocks that are on the move in today's after-hours session.
↗
May 11, 2026
Via
Chartmill
CRA: Here’s the TFSA Contribution Room for 2026 and Why Now Is the Best Time to Use It
↗
March 26, 2026
The CRA confirmed $7,000 in TFSA room for 2026. Here's why AbCellera Biologics could be one of the smartest growth stocks to put that money to work in right now.
Via
The Motley Fool
These stocks are moving in today's after hours session
↗
February 24, 2026
Via
Chartmill
The Biotechnology Renaissance: AI and Capital Collide in a Multi-Trillion Dollar Pivot
February 17, 2026
As of February 17, 2026, the biotechnology sector is undergoing its most significant structural transformation in decades, a period now widely termed the "Biotechnology Renaissance." Following a...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Initial Public Offering
AI Stocks Extend Selloff, Nasdaq 100 Eyes Worst Week Since April: What's Moving Markets Friday?
↗
November 07, 2025
Risk-off sentiment dominated Wall Street on Friday, with selling pressure in AI-linked names intensifying and pushing technology stocks toward their worst week since April.
Via
Benzinga
Topics
Artificial Intelligence
AbCellera Biologics Inc (NASDAQ:ABCL) Reports Mixed Q3 2025 Results with Revenue Beat and Wider Loss
↗
November 06, 2025
AbCellera's Q3 2025 results show revenue beat estimates, but the net loss widened, causing a negative after-hours stock reaction.
Via
Chartmill
AI Stocks Slide Again, Bitcoin Dips Near $100,000: What's Moving Markets Thursday?
↗
November 06, 2025
After a brief and cautious rebound on Wednesday, risk-off sentiment returned sharply on Thursday, with AI-linked stocks leading a broad selloff across Wall Street and renewed pressure hitting crypto...
Via
Benzinga
Topics
Artificial Intelligence
Stock Market Today: Dow Futures Slip, Nasdaq Rises Amid Mixed Trade—AngioDynamics, Entero Therapeutics, Fermi In Focus
↗
October 02, 2025
U.S. stock futures were fluctuating on Thursday following Wednesday's record advances. Futures of major benchmark indices were mixed.
Via
Benzinga
Topics
Stocks
Why Did AbCellera's Stock Jump Over 7% After Hours?
↗
October 02, 2025
AbCellera's stock rose 7.72% in after-hours trading following an 18.49% gain during regular trading, with a strong performance expected in Q3 earnings.
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
↗
August 18, 2025
Via
Benzinga
Expert Outlook: AbCellera Biologics Through The Eyes Of 4 Analysts
↗
August 08, 2025
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
August 08, 2025
Via
Benzinga
AbCellera Biologics (ABCL) Q2 2025 Earnings Call Transcript
↗
August 08, 2025
Via
The Motley Fool
Topics
Earnings
Curious about the stocks that are showing activity after the closing bell on Thursday?
↗
August 07, 2025
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Via
Chartmill
Galaxy Digital, Blaize Holdings, Verizon And Other Big Stocks Moving Higher On Monday
↗
July 21, 2025
Via
Benzinga
Why AbCellera Biologics Stock Raced Nearly 6% Higher Today
↗
June 02, 2025
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
